D-3 PHOSPHORYLATED PHOSPHOINOSITIDES AND ANALOGS

Information

  • Research Project
  • 3498998
  • ApplicationId
    3498998
  • Core Project Number
    R43GM049594
  • Full Project Number
    1R43GM049594-01
  • Serial Number
    49594
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/5/1993 - 32 years ago
  • Project End Date
    4/4/1994 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    4/5/1993 - 32 years ago
  • Budget End Date
    4/4/1994 - 31 years ago
  • Fiscal Year
    1993
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/2/1993 - 32 years ago
Organizations

D-3 PHOSPHORYLATED PHOSPHOINOSITIDES AND ANALOGS

The recently discovered enzyme phosphatidylinositol 3-kinase (PI 3- kinase) physically associates with and is phosphorylated by activated growth factor receptors and oncogenes which manifest protein-tyrosine kinase activity. It phosphorylates phosphatidylinositols specifically at the D-3-hydroxyl to produce the 3-phosphorylated phosphoinositides. 3-PPI. comprising phosphatidylinositol 3-phosphate, PI(3)P, phosphatidylinositol 3,4-bisphosphate, PI(3,4)P2, and phosphatidylinositol 3,4,5-trisphosphate, PI(3,4,5)P3. Mutational studies of growth factor receptors and oncogenes have shown that the associated PI 3-kinase and its products PI(3,4)P2 and PI(3,4,5)P3 regulate cell growth and transformation. The 3-PPI are not physiological substrates for the PI-specific phospholipases C and so the intact lipids have been suggested as novel critical second messengers of growth signals. Biochemical studies to determine the cellular targets of PI(3,4)P2 and PI(3,4,5)P3, the metabolic fate of these lipids, and their roles in the cell cycle have been handicapped because well characterized 3-PPI samples are not readily available, and there is no commercial source. These materials are needed as research probes for defining their biochemical and physiological roles, and may be useful for developing new anticancer agents and applications in medical biotechnology. Practical synthetic methods for 3-PPI are not available. The overall objectives of this proposal are to develop synthetic methods for the 3-PPI and analogues, and to prepare and characterize these by physicochemical and spectrometric techniques. A strategy based on total synthesis and partial synthesis as complementary approaches is suggested. During Phase I, the feasibility of these complementary approaches will be tested for the synthesis of PI(3,4,5)P3, and the product will be fully characterized by analytical, physicochemical and spectrometric measurements. In Phase II, these approaches will be adapted and extended for the syntheses of PI(3)P, PI3,4)P2, isomers and analogues.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    NUTRIMED BIOTECH
  • Organization Department
  • Organization DUNS
  • Organization City
    ITHACA
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    14850
  • Organization District
    UNITED STATES